BR112017016388A2 - cenicriviroc para o tratamento da fibrose - Google Patents

cenicriviroc para o tratamento da fibrose

Info

Publication number
BR112017016388A2
BR112017016388A2 BR112017016388-8A BR112017016388A BR112017016388A2 BR 112017016388 A2 BR112017016388 A2 BR 112017016388A2 BR 112017016388 A BR112017016388 A BR 112017016388A BR 112017016388 A2 BR112017016388 A2 BR 112017016388A2
Authority
BR
Brazil
Prior art keywords
cenicriviroc
fibrosis
treatment
peritonitis
solvate
Prior art date
Application number
BR112017016388-8A
Other languages
English (en)
Inventor
Lefebvre Eric
Original Assignee
Tobira Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics, Inc. filed Critical Tobira Therapeutics, Inc.
Publication of BR112017016388A2 publication Critical patent/BR112017016388A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a divulgação inclui o uso de cenicriviroc ou um sal, ou solvato deste, e composições farmacêuticas contendo o mesmo no tratamento de doenças e distúrbios inflamatórios e do tecido conjuntivo, tais como fibrose, peritonite e lesão hepática.
BR112017016388-8A 2015-02-10 2015-09-22 cenicriviroc para o tratamento da fibrose BR112017016388A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562114304P 2015-02-10 2015-02-10
US62/114,304 2015-02-10
PCT/US2015/051467 WO2016130179A1 (en) 2015-02-10 2015-09-22 Cenicriviroc for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
BR112017016388A2 true BR112017016388A2 (pt) 2018-03-27

Family

ID=56614560

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016388-8A BR112017016388A2 (pt) 2015-02-10 2015-09-22 cenicriviroc para o tratamento da fibrose

Country Status (15)

Country Link
US (3) US20180110754A1 (pt)
EP (1) EP3256124B1 (pt)
JP (2) JP6676660B2 (pt)
KR (1) KR20170113596A (pt)
CN (1) CN107405403B (pt)
AU (1) AU2015382376B2 (pt)
BR (1) BR112017016388A2 (pt)
CA (1) CA2975445A1 (pt)
ES (1) ES2864767T3 (pt)
HK (1) HK1247558A1 (pt)
IL (1) IL253617A0 (pt)
MX (1) MX2017010277A (pt)
RU (1) RU2722641C2 (pt)
SG (1) SG11201706028RA (pt)
WO (1) WO2016130179A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002328092A1 (en) 2001-08-08 2003-02-24 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use as hiv inhibitors
BR112017013130A2 (pt) 2014-12-23 2017-12-26 Tobira Therapeutics Inc processo de fabricação de cenicriviroc e análogos relacionados
CA3028151A1 (en) 2016-06-21 2017-12-28 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
WO2022235440A1 (en) * 2021-04-21 2022-11-10 The United States Government As Represented By The Department Of Veterans Affairs Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2249027A (en) * 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
AU2002328092A1 (en) 2001-08-08 2003-02-24 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use as hiv inhibitors
JPWO2006059716A1 (ja) 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
DK2723360T3 (en) * 2011-06-27 2017-08-28 Université Pierre Et Marie Curie (Paris 6) CCR2 antagonist peptides
AU2014265327B2 (en) * 2013-05-15 2019-08-15 Tobira Therapeutics, Inc. Cenicriviroc compositions and methods of making and using the same
KR101669124B1 (ko) * 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물

Also Published As

Publication number Publication date
CN107405403A (zh) 2017-11-28
HK1247558A1 (zh) 2018-09-28
RU2017130289A3 (pt) 2019-04-22
EP3256124A4 (en) 2018-09-26
US20190343806A1 (en) 2019-11-14
MX2017010277A (es) 2017-12-07
RU2017130289A (ru) 2019-03-12
US20180110754A1 (en) 2018-04-26
WO2016130179A1 (en) 2016-08-18
EP3256124A1 (en) 2017-12-20
US20200360347A1 (en) 2020-11-19
IL253617A0 (en) 2017-09-28
AU2015382376A1 (en) 2017-08-17
JP6676660B2 (ja) 2020-04-08
KR20170113596A (ko) 2017-10-12
CA2975445A1 (en) 2016-08-18
RU2722641C2 (ru) 2020-06-02
CN107405403B (zh) 2021-04-20
SG11201706028RA (en) 2017-08-30
JP2018505218A (ja) 2018-02-22
ES2864767T3 (es) 2021-10-14
EP3256124B1 (en) 2020-12-23
AU2015382376B2 (en) 2021-07-01
JP2020111586A (ja) 2020-07-27

Similar Documents

Publication Publication Date Title
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
MX2016012262A (es) Cenicriviroc para el tratamiento de fibrosis.
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2021009673A (es) Moduladores de ror-gamma.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112016017041A2 (pt) Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112017016388A2 (pt) cenicriviroc para o tratamento da fibrose
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]